Introduction
Skin Analytics is a London-based digital health company founded in 2012 by Neil Daly, who serves as Chief Executive Officer and founder per company news releases reviewed in July 2026. Skin Analytics develops DERM, an artificial intelligence platform for assessing and triaging skin lesions — with particular focus on urgent suspected skin cancer pathways where referral volumes overwhelm dermatology capacity.
Daly has led Skin Analytics since its earliest classical machine learning approaches predating modern deep learning — maintaining a consistent mission of finding and categorizing skin cancers through medical image analysis while evolving technology and regulatory evidence over more than a decade.
What the company does
Skin Analytics’ DERM platform analyzes dermoscopic and clinical images to assess skin lesions, supporting referral triage and — following Class III CE certification — autonomous clinical decisions clearing patients DERM determines do not have cancer without requiring a physician to verify each negative assessment. Daly described this CE mark in company materials as a watershed moment: regulators determining AI can match or exceed specialist doctors in critical clinical assessments in Europe.
Skin Analytics reports deployment since 2020 with more than 170,000 patients seen and over 15,000 cancers found through partner programs — operational scale cited in Daly’s 2025 parliamentary committee testimony and NICE Early Value Assessment commentary on company news posts. DERM integrates into existing care pathways rather than requiring standalone consumer apps — a design aligned with NHS urgent cancer referral workflows.
April 2025 Series B funding of £15 million led by Intrepid Growth Partners supports scaling DERM across European markets and building new care models Daly framed as moving from specialist scarcity to capacity for everyone concerned about their skin.
Who it serves
Skin Analytics serves health systems managing dermatology referral backlogs — particularly UK NHS trusts where over 700,000 urgent skin cancer referrals occurred in 2024 per Daly’s cited statistics in NICE commentary materials. Primary care and teledermatology pathways use DERM to stratify lesions before specialist review, reducing unnecessary urgent referrals while prioritizing high-risk cases. European expansion follows Class III CE certification with rigorous clinical governance commitments Daly outlined for responsible AI adoption.
Company background
Daly founded Skin Analytics in 2012 in London, building computer vision expertise into regulated medical device development over twelve-plus years before Class III autonomous clearance. The company raised successive funding rounds culminating in 2025 Series B, appeared before the UK Parliament Science Innovation and Technology Committee in July 2025, and received NICE Early Value Assessment recommendation for early use while further evidence gathers — milestones Daly referenced when describing adoption speed concerns despite clinical evidence accumulation.
Skin Analytics positions the UK as a leader in regulated AI health deployment while advocating for faster pathway integration when safety evidence supports scale.
Product and AI capabilities
DERM’s AI evolved from classical machine learning to deep learning architectures validated through clinical studies supporting Class III certification — a regulatory tier requiring rigorous evidence for autonomous decisions. Unlike assistive CAD tools, DERM’s cleared autonomous pathway enables negative case clearance without mandatory dermatologist review of each AI output, though health systems retain governance discretion in deployment configurations.
Daly emphasizes AI enabling system redesign toward accessible skin assessment — Series B capital funds geographic scaling and partnership development rather than research-only roadmap items alone.
Key developments
2012: Skin Analytics founded in London by Neil Daly. 2025: DERM Class III CE mark for autonomous skin cancer detection (official news release). April 2025: £15 million Series B funding (official news release). May 2025: NICE Early Value Assessment recommendation referenced in company commentary.
Why it matters
Skin Analytics matters because dermatology access bottlenecks affect cancer outcomes when referrals queue for months — DERM offers a regulated AI pathway to stratify demand if health systems adopt at pace matching evidence generation. Class III autonomous CE mark sets a higher regulatory bar than most dermatology AI triage tools, distinguishing Skin Analytics from assistive apps without clearance. Daly’s parliamentary testimony highlights gap between regulatory approval and operational adoption — a lesson for Brel readers evaluating digital health AI beyond clearance headlines.
Sector context
Skin Analytics belongs in Brel’s AI in healthcare coverage under digital health and medical device AI, distinct from teledermatology platforms without autonomous clearance. Readers should track NICE evidence collection timelines and local governance policies separately from CE certification — approval enables deployment but does not mandate it.
Sources and references
Skin Analytics DERM Class III CE mark release and Series B funding announcement (April 2025).
- Skin Analytics — DERM Class III CE mark (skin-analytics.com)
- Skin Analytics — £15M Series B (skin-analytics.com, April 2025)
Reviewed July 10, 2026. Neil Daly is founder and CEO. england.nhs.uk removed per batch 3 rules.